GPR37 activation by its neuropeptide ligand, prosaptide, has been shown to protect dopaminergic neurons from oxidative stress and reduce the aggregation of α-synuclein [75], suggesting GPR37 as an attractive target for developing disease-modifying therapies aimed at preventing neuronal degeneration in PD. This evidence concerns the gene GPR37 and Parkinson disease.